Is Arbutus Biopharma Corp (ABUS) a Buy, Sell, or Hold?
Arbutus Biopharma Corp
NASDAQ:ABUS
$4.61 USD
-$0.06 (-1.18%)
- Volume
- 1.69M
- Average Volume
- 2.15M
- Market Capitalization
- $910.65M
- P/E Ratio
- 5.53
- Dividend Yield
- 0.00%
- Price Target
- $8.50
- Year High
- $5.38
- Year Low
- $3.08
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $54.26
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Lindsay Androski |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ABUS |
| CUSIP | 03879J100 |
| CIK | 0001447028 |
| Web | http://www.arbutusbio.com |
| Phone | 267 469 0914 |
| Currency | USD |
| Employees | 19 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 54.26 |
| Quick Ratio | 54.26 |
| Cash Ratio | 4.64 |
Sales & Book Value
| Annual Sales | $14.08M |
| Price / Sales | 4.76 |
| Cash Flow | -0.18 |
| Price / Cash Flow | -26.51 |
| Price / Book | 3.43 |
Price Target and Rating
| Average Stock Price Forecast | $8.50 |
| High Stock Price Forecast | $8.50 |
| Low Stock Price Forecast | $8.50 |
| Forecast Upside/Downside | -45.76% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.17 |
| Trailing P/E Ratio | 5.53 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-33.5M |
| Net Margin | 83.95% |
| Pretax Margin | 83.95% |
| Return on Equity | 129.32% |
| Return on Assets | 57.99% |
Financials Score
| AltmanZ Score | 31.16 |
| Piotroski Score | 6.00 |
| Working Capital | 271.91M |
| Total Assets | 277.16M |
| Ebit | 160.81M |
| Market Cap | 948.18M |
| Total Liabilities | 16.99M |
Poll Results
About Arbutus Biopharma Corp (NASDAQ:ABUS) Stock
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Ar ... butus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma: Moderna Validates My IP Bull Case
2026-07-13 08:00:00
Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusiran has shown durable viral control. The main caveat is that it comes from combo therapies. Their balance sheet gives them a comfortable runway to pursue imdusiran's upcoming Phase 2b trial, which is yet another optionality vertical for the stock.
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-13 07:30:00
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna
2026-04-15 07:30:00
Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B (“cHBV”).
Frequently Asked Questions
-
What is the current Arbutus Biopharma Corp (ABUS) stock price?
-
Arbutus Biopharma Corp(NASDAQ:ABUS) stock price is $4.61 in the last trading session. During the trading session, ABUS stock reached the peak price of $5.38 while $3.08 was the lowest point it dropped to. The percentage change in ABUS stock occurred in the recent session was --1.18% while the dollar amount for the price change in ABUS stock was -$-0.06.
-
ABUS's industry and sector of operation?
-
The NASDAQ listed ABUS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ABUS?
-
Andrew J. Sung | General Counsel
R. Hector Mackay-Dunn | Corporate Secretary
Tuan Nguyen | Chief Financial Officer
Lindsay Androski | President, Chief Executive Officer & Chairman
| -
How many employees does ABUS have?
-
Number of ABUS employees currently stands at 19. ABUS operates from 701 Veterans Circle, Warminster, PA 18974, US.
-
Link for ABUS official website?
-
Official Website of ABUS is: http://www.arbutusbio.com
-
How do I contact ABUS?
-
ABUS could be contacted at phone #267 469 0914 and can also be accessed through its website. ABUS operates from 701 Veterans Circle, Warminster, PA 18974, US.
-
How many shares of ABUS are traded daily?
-
The average number of ABUS shares traded daily for last 3 months was 2.15M.
-
What is the market cap of ABUS currently?
-
The market value of ABUS currently stands at $910.65M with its latest stock price at $4.61